<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545035</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1718</org_study_id>
    <nct_id>NCT03545035</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study</brief_title>
  <acronym>LLC178</acronym>
  <official_title>Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ERIC Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at obtaining more in-depth information on how patients with chronic&#xD;
      lymphocytic leukemia treated with idelalisib and rituximab react to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cohort study will recruit patients with treatment-naïve chronic lymphocytic leukemia&#xD;
      (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were&#xD;
      treated with idelalisib and rituximab between 01/07/2014 and 31/05/2017 at European centres&#xD;
      adhering to the GIMEMA group and the ERIC group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients responding to treatment</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Efficacy profile of idelalisib and rituximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing toxicities</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Safety profile of idelalisib and rituximab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive without progression of the disease</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Progression-free-survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving response</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>All patients being observed during the study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idelalisib and rituximab</intervention_name>
    <description>patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This cohort study will recruit patients with treatment-naïve chronic lymphocytic leukemia&#xD;
        (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who&#xD;
        were treated with idelalisib and rituximab between 01/07/2014 and 31/05/2017 at European&#xD;
        centres adhering to the GIMEMA group and the ERIC group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CLL / Small Lymphocytic Lymphoma (CLL/SLL) according to the World Health&#xD;
             Organisation (WHO) classification 2008.&#xD;
&#xD;
          -  Treatment with idelalisib and rituximab started between the date of Country marketing&#xD;
             authorization approval of idelalisib (EMA approval 18/09/2014) and 31/05/2017 given at&#xD;
             European centres adhering to the GIMEMA group and the ERIC group.&#xD;
&#xD;
          -  One of the two following conditions must be satisfied:&#xD;
&#xD;
               -  Previously untreated CLL requiring therapy according to the NCI criteria (Hallek&#xD;
                  M et al, Blood 2008)] with deletion 17p13 and/or TP53 mutation.&#xD;
&#xD;
               -  Relapsed refractory CLL., i.e. patients who received at least one previous line&#xD;
                  of treatment using alkylating agents and/or purine analogues with or without&#xD;
                  monoclonal antibodies, or high dose steroids requiring therapy according to the&#xD;
                  NCI criteria (Hallek M et al, Blood 2008)&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Signed written informed consent, if applicable, according to ICH/EU/GCP and national&#xD;
             local law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with CLL treated with idelalisib within interventional clinical trials or&#xD;
             outside the approved indication.&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  Transformation of CLL to aggressive lymphomas (Richter's Syndrome).&#xD;
&#xD;
               -  HIV infection.&#xD;
&#xD;
               -  Active and uncontrolled HCV and/or HBV infections or liver cirrhosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cuneo</last_name>
    <role>Study Chair</role>
    <affiliation>Ematologia; Azienda Ospedaliera di Ferrara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gian Matteo Rigolin</last_name>
    <role>Study Director</role>
    <affiliation>Ematologia; Azienda Ospedaliera di Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>+39 06 70390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>+39 06 70390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>GianMatteo Rigolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti &quot;Umberto I - G.M. Lancisi - G. Salesi&quot;- Ancona- Sod Clinica Ematologica</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Scortechini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Brotzu, PO A.Businco - SC Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Murru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Di Catanzaro &quot;Pugliese-Ciaccio&quot;, Presidio Ospedaliero &quot;Ciaccio - de Lellis&quot; - Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Careggi - Firenze - Sod Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Ciolli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti &quot;Papardo Piemonte&quot; - Po Papardo - Messina - Sc Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico P. Giaccone - Palermo - Uo Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Siragusa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Di Parma - Sc Ematologia E Centro Trapianti Midollo Osseo</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Re</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Di Piacenza - Ospedale &quot;Guglielmo Da Saliceto&quot; - Ematologia E Centro Trapianti</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Vallisa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Regionale S. Carlo - Potenza - Sic Ematologia</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Pizzuti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ausl Di Reggio Emilia - Arcispedale Santa Maria Nuova - Irccs - Sc Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorella Ilariucci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna, Ospedale &quot;Infermi&quot; - Rimini - Uo Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lia Molinari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Tor Vergata - UOC Trapianto cellule staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Del Poeta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi Di Roma &quot;Sapienza&quot; - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Mauro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Senese - Policlinico &quot;Le Scotte&quot; - UOC EMATOLOGIA E TRAPIANTI</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gozzetti, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Coscia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Quaglia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Idelalisib</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

